Russia starts mass rollout of Sputnik coronavirus vaccine
he most vulnerable will receive the first doses of the vaccine named Sputnik V, including medical workers and teachers
/NOVOSTIVL/ The city of Moscow has begun opening 70 vaccination facilities where thousands of doctors, teachers and others in high-risk groups had signed up to receive COVID-19 vaccines starting Saturday, a precursor to a sweeping Russia-wide immunisation effort.
Britain is meanwhile preparing to become the first country to roll out the Pfizer/BioNTech COVID-19 vaccine this week, and will initially make the shot available at hospitals before distributing stocks to doctors' clinics, the government said on Sunday.
Russia's vaccination centres started giving shots to willing recipients three days after President Vladimir Putin ordered the launch of a “large-scale” COVID-19 immunisation campaign even though a Russian-designed vaccine has yet to complete the advanced studies needed to ensure its effectiveness and safety in line with established scientific protocols.
Russia boasted that Sputnik V was the world’s “first registered COVID-19 vaccine” after the government gave it regulatory approval in early August. The move drew criticism from international experts, who pointed out that the vaccine had only been tested on several dozen people at the time.
Putin has shrugged off doubts about it, saying in August that one of his daughters was among the early vaccine recipients.
Sputnik V has been offered to medical workers and teachers for several months even though the vaccine was still in the middle of advanced trials. Several top Russian officials said they had gotten the required two jabs, and the Russian military this week began vaccinating the crews of navy ships scheduled to depart on a mission.
Health Minister Mikhail Murashko said on Wednesday that more than 100,000 people in Russia have received the shots.
Russia is offering the vaccine for free to people aged 18 to 60 who don’t suffer from chronic illnesses and aren’t pregnant or breastfeeding.
The two-shot Sputnik V was developed by the Moscow-based Gamaleya Institute. An advanced study among 40,000 volunteers was announced two weeks after the vaccine received government approval and that is still ongoing.
Kirill Dmitriyev, head of the Russian Direct Investment Fund that bankrolled Sputnik V’s development, said last month that more than 1 billion doses of the vaccine were expected to be produced outside of Russia next year.
Last month, developers of the vaccine said interim analysis of trial data showed it was 91.4% effective. The conclusion was based on 39 infections among 18,794 study participants that received both doses of either the vaccine or a placebo, which is a much lower number of infections than Western drugmakers have looked at when assessing the effectiveness of their vaccines. Two other Russia-designed vaccines are also undergoing tests.